213 related articles for article (PubMed ID: 26122273)
1. 4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.
Takamatsu Y; Tanaka Y; Kohgo S; Murakami S; Singh K; Das D; Venzon DJ; Amano M; Higashi-Kuwata N; Aoki M; Delino NS; Hayashi S; Takahashi S; Sukenaga Y; Haraguchi K; Sarafianos SG; Maeda K; Mitsuya H
Hepatology; 2015 Oct; 62(4):1024-36. PubMed ID: 26122273
[TBL] [Abstract][Full Text] [Related]
2. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
[TBL] [Abstract][Full Text] [Related]
3. 7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.
Hayashi S; Higashi-Kuwata N; Das D; Tomaya K; Yamada K; Murakami S; Venzon DJ; Hattori SI; Isogawa M; Sarafianos SG; Mitsuya H; Tanaka Y
Antiviral Res; 2020 Apr; 176():104744. PubMed ID: 32084506
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
Higashi-Kuwata N; Hayashi S; Kumamoto H; Ogata-Aoki H; Das D; Venzon D; Hattori SI; Bulut H; Hashimoto M; Otagiri M; Takamune N; Kishimoto N; Davis DA; Misumi S; Kakuni M; Tanaka Y; Mitsuya H
J Hepatol; 2021 May; 74(5):1075-1086. PubMed ID: 33333207
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
6. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
Yasutake Y; Hattori SI; Hayashi H; Matsuda K; Tamura N; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2018 Jan; 8(1):1624. PubMed ID: 29374261
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
Mukaide M; Tanaka Y; Shin-I T; Yuen MF; Kurbanov F; Yokosuka O; Sata M; Karino Y; Yamada G; Sakaguchi K; Orito E; Inoue M; Baqai S; Lai CL; Mizokami M
Antimicrob Agents Chemother; 2010 Feb; 54(2):882-9. PubMed ID: 19933798
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
Liu Y; Zhou Y; Li X; Niu M; Chen R; Shao J; Si L; Luo D; Lin Y; Li L; Zhang K; Xiao X; Xu Z; Liu M; Lu M; Zoulim F; Xu D
Emerg Microbes Infect; 2019; 8(1):354-365. PubMed ID: 30866789
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Rawal RK; Konreddy AK; Chu CK
Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of an entecavir-resistant hepatitis B virus variant.
Yatsuji H; Hiraga N; Mori N; Hatakeyama T; Tsuge M; Imamura M; Takahashi S; Fujimoto Y; Ochi H; Abe H; Maekawa T; Suzuki F; Kumada H; Chayama K
J Med Virol; 2007 Dec; 79(12):1811-7. PubMed ID: 17935165
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hepatitis B virus polymerase by entecavir.
Langley DR; Walsh AW; Baldick CJ; Eggers BJ; Rose RE; Levine SM; Kapur AJ; Colonno RJ; Tenney DJ
J Virol; 2007 Apr; 81(8):3992-4001. PubMed ID: 17267485
[TBL] [Abstract][Full Text] [Related]
14. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
Takamatsu Y; Das D; Kohgo S; Hayashi H; Delino NS; Sarafianos SG; Mitsuya H; Maeda K
Cell Chem Biol; 2018 Oct; 25(10):1268-1278.e3. PubMed ID: 30174310
[TBL] [Abstract][Full Text] [Related]
15. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
16. Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4'-modified nucleoside RT inhibitors.
Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
Biochem Biophys Res Commun; 2019 Feb; 509(4):943-948. PubMed ID: 30648556
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.
Stoddart CA; Galkina SA; Joshi P; Kosikova G; Moreno ME; Rivera JM; Sloan B; Reeve AB; Sarafianos SG; Murphey-Corb M; Parniak MA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4190-8. PubMed ID: 25941222
[TBL] [Abstract][Full Text] [Related]
18. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
[TBL] [Abstract][Full Text] [Related]
19. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
Kawamoto A; Kodama E; Sarafianos SG; Sakagami Y; Kohgo S; Kitano K; Ashida N; Iwai Y; Hayakawa H; Nakata H; Mitsuya H; Arnold E; Matsuoka M
Int J Biochem Cell Biol; 2008; 40(11):2410-20. PubMed ID: 18487070
[TBL] [Abstract][Full Text] [Related]
20. Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.
Domaoal RA; McMahon M; Thio CL; Bailey CM; Tirado-Rives J; Obikhod A; Detorio M; Rapp KL; Siliciano RF; Schinazi RF; Anderson KS
J Biol Chem; 2008 Feb; 283(9):5452-9. PubMed ID: 17962184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
